HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

Phase 2TerminatedNCT03351855

Shenzhen Geno-Immune Medical Institute100 enrolled

Overview

The purpose of this clinical trial is to evaluate the safety and efficacy of IV-infused autologous or allogenic HPV-CTLs.

Human papilloma viruses (HPV) have been consistently implicated in causing cervical cancer especially those high-risk types (HPV 16, 18, 31, 45). Around 50-80% of women are infected by HPV within their whole lives. The current treatment of HPV-positive mainly includes drug, cryotherapy, laser, microwave, surgery and so on. Some treatments are convenient, but easy to cause pain or infection and there is still a greater risk of recurrence after treatment. Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) reactive with specific viral antigens has proven to be effective. Here, the investigators aim to evaluate the safety and efficacy of multiple infusions of HPV specific cytotoxic T lymphocytes cells in patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Human Papilloma Virus

Interventions

HPV-CTLsBIOLOGICAL

2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg by IV each time

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Written, informed consent obtained prior to any study-specific procedures. 2. Evidence of HPV virus activation (viral DNA) or high risk of HPV infection. 3. Not suitable for routine treatment or invalid to antiviral drugs. 4. Patients with viral disease symptoms and confirmed by biopsy, regardless of the level of virus DNA. 5. Age less than 75 years. 6. Did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics. 7. Initial hematopoietic reconstitution: neutrophils (ANC) ≥ 1,000/mm\^3, platelet (PLT) ≥ 1,000/mm\^3. 8. Proper renal and hepatic functions (ULN denotes "upper limit of normal range"): Creatinine ≤ 2\*ULN, Bilirubin ≤ 2\*ULN, SGOT/ SGPT ≤ 3\*ULN. 9. If HPV-CTL is not from the patient's own, then the provider of HPV-CTL needs to meet the following criteria: * did not receive chemotherapy or radiotherapy within 4 weeks prior to blood collection, and did not take any steroids for the previous week, did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics. * white blood cells ≥ 3,500 / μl, lymphocytes ≥ 750 / μl. 10. Human immunodeficiency virus (HIV) test was negative. Exclusion Criteria: 1. Subject or the donor of BMT recipient infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive), Treponema pallidum antibody positive or TB culture positive. 2. Subject is albumin-intolerant. 3. Subject with life expectancy less than 8 weeks. 4. Subject participated in other investigational somatic cell therapies within past 30 days. 5. Subject with positive pregnancy test result.

Locations (1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China

Outcomes

Primary Outcomes

Safety of HPV-CTLs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events

Physiological parameter (measuring cytokine response, fever, symptoms)

Time frame: 6 months

Secondary Outcomes

Viral load response

The viral load response to the CTLs infusion will be assessed by HPV specific PCR of peripheral blood.

Time frame: 6 months

Treatment Responses

Disease status is defined by the biochemical markers (measuring HPV concentration and so on) to get the outcomes such as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.